Repositioning Candidate Details
| Candidate ID: | R1588 |
| Source ID: | DB16028 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Azemiglitazone |
| Synonyms: | Azemiglitazone |
| Molecular Formula: | C19H17NO5S |
| SMILES: | COC1=CC=CC(=C1)C(=O)COC1=CC=C(CC2SC(=O)NC2=O)C=C1 |
| Structure: |
|
| DrugBank Description: | Azemiglitazone is under investigation in clinical trial NCT01280695 (A Randomized, Double-blind, Comparator- and Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients). |
| CAS Number: | 1133819-87-0 |
| Molecular Weight: | 371.41 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | -- |
| Targets: | Peroxisome proliferator-activated receptor gamma |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|